Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 107 publications
Dupilumab treatment improves signs, symptoms, and quality of life in children aged 6 months to 11 years with moderate-to-severe atopic dermatitis: a plain language summary.
Journal: The Journal of dermatological treatment
Published: August 24, 2026
Dupilumab Provides Meaningful Clinical Responses in Harlequin Ichthyosis (ABCA12-nEDD): A Report of Two Cases.
Journal: Pediatric dermatology
Published: February 15, 2026
Cutaneous features of SDR9C7 variants in eight subjects with autosomal recessive nonsyndromic epidermal differentiation disorders.
Journal: Clinical and experimental dermatology
Published: February 11, 2026
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study.
Journal: Journal of the American Academy of Dermatology
Published: December 15, 2025
Growth Assessment in Children Under 12 Years With Moderate-to-Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry.
Journal: Pediatric dermatology
Published: November 10, 2025
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.
Journal: The British journal of dermatology
Published: October 30, 2025
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis.
Journal: American journal of clinical dermatology
Published: September 24, 2025
Off-label use of commercially available topical sirolimus for keratosis pilaris rubra faciei.
Journal: JAAD case reports
Published: February 19, 2025
Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials.
Journal: Journal of the American Academy of Dermatology
Published: November 13, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
Journal: JAMA dermatology
Published: October 23, 2024
Live Attenuated Vaccine Administration in Children Treated With Methotrexate or Dupilumab.
Journal: Pediatric dermatology
Published: July 25, 2024
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
Journal: The Journal of dermatological treatment
Published: May 12, 2024
Last Updated: 09/26/2026